Driven by a commitment to provide access to life-saving medicines worldwide, Shaw brings extensive experience in biotherapeutics, strategic leadership, financial and business development and a dedication to improving patients’ lives to the company’s board of industry leaders, PureTech said in a statement.
“Kiran brings a wealth of experience and knowledge to PureTech’s board as we enter this next exciting chapter of growth,” PureTech’s Board of Directors Chairman Christopher Viehbacher said.
Since she founded Biocon, Shaw has guided its growth from a leading bioenzymes company of India to a fully integrated and globally recognised multibillion-dollar biopharma company with extensive research efforts in oncology, diabetes and autoimmune disease, the statement said.
“I am thrilled to join the luminaries on PureTech’s board at a time when the company is poised for rapid growth building on the many successes of recent years,” Mazumdar-Shaw said.
On joining the board, Shaw will become a member of the board’s Remuneration and Nomination Committees, the statement said.
“Her proven track record of entrepreneurial ingenuity and integrity along with her demonstrated business leadership position her as an excellent addition to PureTech’s board of industry leaders. We are excited to work with her as we continue on our growth trajectory,” PureTech Founder and CEO Daphne Zohar said.